Molecular, clinical, and therapeutic determinants of outcome in <i>NPM1</i>-mutated AMLJad Othman, Richard Dillon, Charlotte S. Wilhelm-Benartzi et al.|Blood|2024Cited by 78
A randomized comparison of CPX-351 and FLAG-Ida in adverse karyotype AML and high-risk MDS: the UK NCRI AML19 trialJad Othman, Nigel H. Russell, Claire Hemmaway et al.|Blood Advances|2023Cited by 53